Publicacións nas que colabora con Ignacio Gil Bazo (18)

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

2020

  1. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    TH Open

  2. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

  3. The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients

    Disease Markers, Vol. 2019

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

  2. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

  3. Targeted DNA sequencing for assessing clonality in multiple lung tumors: A new approach to an old dilemma

    Lung Cancer, Vol. 122, pp. 120-123

2017

  1. Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer

    Hospital practice (1995), Vol. 45, Núm. 3, pp. 70-75

  2. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

    Cancer Letters, Vol. 402, pp. 43-51

2016

  1. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

2015

  1. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

2013

  1. Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy

    Journal of Translational Medicine, Vol. 11, Núm. 1

2012

  1. The multimodal management of locally advanced N2 non-small cell lung cancer: Is there a role for surgical resection? A single institution's experience

    Clinical and Translational Oncology, Vol. 14, Núm. 11, pp. 835-841

2009

  1. Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer

    Lung Cancer, Vol. 64, Núm. 1, pp. 124-126

  2. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

    World Journal of Gastroenterology, Vol. 15, Núm. 18, pp. 2290-2292

  3. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin b12 and folic acid supplementation for advanced non-small cell lung cancer

    Onkologie, Vol. 32, Núm. 10, pp. 580-584